Generic placeholder image

Mini-Reviews in Medicinal Chemistry

Editor-in-Chief

ISSN (Print): 1389-5575
ISSN (Online): 1875-5607

Histone Deacetylase Inhibitors: A Review on Class-I Specific Inhibition

Author(s): Jagannath Behera, Venkatesan Jayaprakash and Barij Nayan Sinha

Volume 15, Issue 9, 2015

Page: [731 - 750] Pages: 20

DOI: 10.2174/1389557515666150521162237

Price: $65

Abstract

Histone Deacetylase (HDAC) is an established and validated target for the treatment of cancer. It has been attempted to present a comprehensive review on the inhibitors for Class-I Histone Deacetylase enzyme family, reported during the period from 2002 to 2012. This review has summarized the inhibitors, based on their specificity towards different isoforms within this class. Further various recent United State (US) patents and the HDAC inhibitors, used singly or in combination undergoing clinical trial as anticancer agents have been reviewed. Three such inhibitors SAHA, Romidepsin and Belinostat have already been approved by the US-FDA for the treatment of cancer.

Keywords: Histone Deacetylase, cancer, isoform, Romidepsin, US-FDA.


Rights & Permissions Print Cite
© 2024 Bentham Science Publishers | Privacy Policy